The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
OBJECTIVE
To investigate the characteristics of Hep-2 cell with multidrug resistance (MDR) induced by Taxol.


METHODS
Hep-2 cells were exposed in stepwise escalating concentration of Taxol to develop the resistant cell line-Hep-2T. Cell cycle distribution, apoptosis, and rhodamine accumulation were studied through flow cytometry. The MDR1 and MRP1 genes were detected through real-time quantitative RT-PCR, and the corresponding proteins were detected through Western blotting.


RESULTS
The drug resistance of Hep-2T cells to Taxol, doxorubicin, gemcitabine, 5-FU, and cisplatin all increased. The percentage of G0/G1 phase and the antiapoptosis ability increased significantly compared with Hep-2 cells. Both MDR1 and MRP1 also increased at gene and protein level, though MDR1 was more prominent.


CONCLUSIONS
More emphasis should be laid on MDR1/Pgp, the non-Pgp substrate chemotherapeutic agents, and the changes of cell cycle distribution to prevent MDR induced by Taxol.


CONCLUSIONS
These findings may provide theoretical support for the reverse of MDR.
Li
Li
L
Department of Otolaryngology, Shanghai Jiao Tong University affiliated First People's Hospital, China.
Jiang
Alice C
AC
Dong
Pin
P
Wan
Yi
Y
Yu
Zi Wei
ZW
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000032:analysis; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000032:analysis; D017239:Paclitaxel / Q000627:therapeutic use*; D020112:Rhodamine 123; D000093542:Gemcitabine
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D002945:Cisplatin; D003841:Deoxycytidine; D004317:Doxorubicin; D005456:Fluorescent Dyes; D005472:Fluorouracil; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D017239:Paclitaxel; D020112:Rhodamine 123; D000093542:Gemcitabine; C513055:ABCB1 protein, human; C421109:multidrug resistance-associated protein 1